Time and date for ASH,
Title: Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide and HMA Naïve (Abstract #463)
Session Name: 637. Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics II
Session Date: Sunday, December 2, 2018
Session Time: 4:30 p.m. PT - 6:00 p.m. PT
Presentation Time: 4:30 p.m. PT
The oral presentation is expected to provide more mature efficacy and safety data from the combined initial and expansion cohorts in Part 1 of IMerge, a Phase 2 clinical trial of imetelstat in transfusion dependent, lower risk myelodysplastic syndromes (MDS) patients who are relapsed or refractory to an erythropoiesis stimulating agent (ESA), do not have a del(5q) chromosomal abnormality and are hypomethylating agent (HMA) and lenalidomide treatment naïve.
Title: Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels (Abstract #685)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Emerging Therapies and Prognostic Scoring in Myelofibrosis and Other MPNs
Session Date: Monday, December 3, 2018
Session Time: 10:30 a.m. PT - 12:00 p.m. PT
Presentation Time: 10:30 a.m. PT
The oral presentation will highlight efficacy and safety data from a primary analysis of IMbark, a Phase 2 clinical trial that evaluated two starting dose levels of imetelstat (either 4.7 mg/kg or 9.4 mg/kg administered by intravenous infusion every three weeks) in more than 100 patients with Intermediate-2 or High-risk myelofibrosis (MF) who have relapsed after or are refractory to prior treatment with a JAK inhibitor. More mature data from the extension phase of IMbark, including median overall survival, is expected to be presented.
